Paradigm shift in oncology: The emergence of point-of-care diagnostic technology

July 22, 2026 - 03:34

The dream of getting cancer test results faster, more accurately, and at a lower cost is moving closer to reality. This shift is being driven by interdisciplinary teams who are rethinking how diagnostics are delivered. Brian Cunningham, a program leader at the Cancer Center at Illinois, is at the forefront of this movement. His work focuses on moving complex lab tests out of centralized hospitals and into small, portable devices that can be used in a doctor's office or even a pharmacy.

This is not just about convenience. Traditional cancer diagnostics often require sending samples to a specialized lab, waiting days for results, and dealing with high costs. Point-of-care technology aims to bypass that entire chain. Using microfluidics, advanced optics, and biosensors, these new devices can analyze a tiny drop of blood or tissue in minutes. They look for biomarkers, genetic mutations, or circulating tumor cells with a level of precision that was previously only possible in a full-scale laboratory.

The implications for patient care are significant. A doctor could screen for early-stage cancer during a routine checkup. A patient undergoing treatment could have their response monitored in real time, without needing to travel to a major medical center. This speed could be critical for catching recurrences early. While challenges remain in scaling production and ensuring regulatory approval, the direction is clear. The future of oncology may rely less on massive machines and more on handheld tools that put the power of diagnosis directly into the hands of the clinician.